Left Ventricular Hypertrophy in Fabry's Disease in an Old Male Patient by Firuzi, Mohadese et al.
Inpress Article 
 
Copyright © 2020 The Author(s); Published by International Journal of Cardiovascular Practice. This is an open access article, distributed under the terms of 
the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses /by-nc/4.0/) which permits others to copy 
and redistribute material just in noncommercial usages, provided the original work is properly cited. 






Fabry disease is an X-linked disorder due to deficiency of the lysosomal hydrolasea-
galactosidase A and the resultant accumulation of glycosphingolipids throughout the 
body, such as in the heart. Cardiac manifestations in Fabry disease are due to 
glycosphingolipid deposition in the myocardium, valves, and conduction system. Fabry 
cardiomyopathy, characterized by progressive severe concentric left ventricular 
hypertrophy. We, as a result of this, have reported a case of Fabry disease with left 
ventricular hypertrophy. He was admitted with dyspnea and also dizziness, general 
weakness, and acroparesthesias. Physical examination showed Angiokeratoma on the 
skin. The electrocardiography revealed ST-segment depression in leads V3–V6, and 
changes related to left ventricular hypertrophy. Echocardiography showed concentric 
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INTRODUCTION
Fabry disease (FD) is a devastating, progressive, 
hereditary, and rare X-linked recessive genetic 
disorder of sphingolipid storage disorder 
characterized by the deficiency of the lysosomal 
enzyme α-galactosidase A [1, 2]. This enzymatic 
defect leads to progressive pathologic intracellular 
deposition of globotriaosylceramide (Gb3) and 
galactosylceramide, the major glycosphingolipid 
substrates of α-galactosidase A, in the whole body, 
especially the skin, nervous system and solid organs 
such as kidney, eye, and heart [3]. A common 
manifestation of FD includes angiokeratomas of skin, 
asymptomatic corneal dystrophy (cornea verticillata 
and posterior lenticular cataract), severe and early 
cerebrovascular disease, strokes, infrequent attacks of 
neuropathic pains and renal failure have been 
documented [4]. Precipitates of glycosphingolipid in 
the different parts of the heart, such as myocardium, 
valves, and conduction system, affect the function 
and structure of the heart. This change is the cause of 
various cardiac manifestations in FD [5]. The most 
crucial feature of Fabry cardiomyopathy is the 
thickening of the left ventricular wall, without 
significant dilatation and enlargement of the cavity, 
which Fabry cardiomyopathy classified by the 
severity of the wall thickening. In fact, the most 
common abnormal structural pattern of Fabry 
cardiomyopathy is left ventricular hypertrophy. 
(LVH), which may mimic the morphologic and 
clinical features of hypertrophic cardiomyopathy [6]. 
LVH in FD is the most important cause of death in 
affected patients [7]. Electrocardiographic 
abnormalities also occur in FD. These changes 
include varying degrees of atrial conduction block, 
tachyarrhythmia, and ST / T wave abnormalities. [8]. 
Other cardiovascular complications of FD can be 
Mitral valve prolapse, thromboembolic events, 
various cardiac arrhythmias, and sudden death at any 
time of cardiovascular involvement [6]. Rarely the 
heart can be the only organ involved called "cardiac 
variant." This condition has been shown in 3% and 
6% of male and female patients with LVH, 
respectively [9]. We have now reported a case of FD 
with LVH. 
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CASE PRESENTATION 
History and Physical Findings 
A 59-year-old male patient confirmed the case of FD 
based on documents, and also, His medical history 
shows hypertension, renal transplantation due to renal 
failure, 11 years later, Two times and transient ischemic 
attacks. He was admitted with exertional dyspnea. He 
also complained of dizziness, general weakness, and 
acroparesthesias. The patient had no personal or family 
history of heart disease based on before 
electrocardiography (ECG), echocardiographic 
examination, and other documents. On review at first 
hospitalization, his body temperature, heart rate, and 
blood pressure were 37.1°C, 94 bit/Min, 145/90 
mmHg, respectively. On physical examination of the 
skin showed small, raised, and dark-red spots which 
suggestive of Angiokeratoma (Fig 1). Eye fundoscopy 
and physical examination of other organs were normal.  
 
 




The ECG changes at admission revealed sinus 
tachycardia relatively with ST-segment depression in 
leads V3–V6, Ι and V1, and modifications related to 
voltage criteria of LVH. 
Echocardiography 
Parasternal long-axis echocardiography showed 
concentric LVH. The systolic septum width was 25 mm, 
diastolic 23 mm. Global ejection fraction decreased to 
40% (Fig 2). 
Laboratory Investigations 
The initial complete blood count revealed a hemoglobin 
count of 9.2 g/dL with Mean corpuscular volume 82.1, 
which suggests chronic disease anemia. A 
complementary laboratory workup showed that 
cholesterol, triglyceride, and low-density lipoprotein 
levels were a high level of normal limits. Also, high-
density lipoprotein was low at 34 mg/dl (normal: >50 
mg/dl). Arterial blood gases showed metabolic acidosis. 
Both blood urea nitrogen and creatinine were elevated 
to 94 mg/dl and 9.4 mg/dl, respectively. Serum levels of 
albumin were low. 
His serum electrolytes levels, the erythrocyte 
sedimentation rate and C-reactive protein, coagulation 
screening tests, and other laboratory investigations were 
within normal limits (or negative). 
 
 
Figure 2. Apical 4 chamber view of echocardiography revealing 
diffuse left ventricular hypertrophy with increases septal thickness 
 
Treatment and Follow up 
Although enzyme replacement therapy (ERT) is a 
specific treatment for FD; however, we have not 
accessed to those. Thus, in addition to the particular 
management for each organ, according to cardiac 
findings, captopril and carvedilol were begun. He is 
being followed up now. 
DISCUSSION 
Epidemiological Aspects 
Different literature reports the incidence of FD, ranging 
from 1 in 476,000 in some studies to 117,000 in other 
studies [10]. And even in some other studies are high, as 
high as 1 in 3,100 [11]. Although our review was male, 
the prevalence of FD in women is four times (3% vs. 
12%) for men. There is also a higher prevalence of FD 
complications in women, but these complications are 
rare and usually mild and progress slowly [12]. The early 
step of FD starts in the fetal stage of infancy. However, 
most patients are clinically asymptomatic during 
infancy, against too many other lysosomal storage 
diseases [13]. The first clinical symptoms start in 
childhood and between the ages of 3 to10 years, a few 
years later in girls than in boys. Advanced organ systems 
damage extend to organ failure in both genders, over 
timing [14]. LVH most commonly occurs in the fourth 
or fifth decade, at an average age of 32 years and 40 years 
in men and in women, respectively [15]; however, our 
case was diagnosed at 59 years old. 
Etiology 
FD is caused by a deficit in the lysosomal enzyme α-
galactosidase A (α-Gal A), the resulting gene mutation, 
International Journal of Cardiovascular Practice  Firuzi, et al. 
3 
which is located in the X chromosome region Xq22 (3). 
Lysosomal enzyme α-Gal A deficiency makes to 
deposition of Gb3 and galactosylceramide in many cells 
of the whole body, such as capillary endothelial cells, 
renal (podocytes, tubular cells, glomerular endothelial, 
mesangial and interstitial cells), cardiac 
(cardiomyocytes and fibroblasts) and nerve cells [16]. 
Cardiac involvement in FD due to deposition of 
glycosphingolipid in the different parts of the heart, such 
as myocardium, valves, and conduction system that 
caused structural and functional changes. These 
depositions in the heart is like to deposition in other 
organs. Although deposition of glycosphingolipid may 
be seen in all cardiac tissues; however, the major 
concentrations of depositions happen in the left 
ventricular myocardium, the mitral valve and the left 
atrium [17, 18]. 
Histopathology 
The histopathology of FD is that Gb3 and 
digalactosylamide deposition occur in the cells of the 
body that causing cellular dysfunction and resulting in 
histopathologic events. These events include cell death, 
compromised energy metabolism, small vessel injury, 
impaired K channel function in endothelial cells, 
oxidative stress, autophagosome maturation, tissue 
ischemia, and most importantly, Irreversible cardiac and 
kidney tissue fibrosis [19-21]. 
The pattern of cardiac hypertrophy in FD differs from 
hypertensive cardiomyopathy or other infiltrative 
cardiomyopathies. The literature reports that the 
Lysosomal deposits, increased contractile proteins, 
myocyte volume, and consequently left ventricular 
muscle mass may contribute to left ventricular 
hypertrophy [17, 22]. 
Manifestation 
The early clinical symptoms of FD begin in childhood 
[14]. Whole-body cells are affected in FD, including 
renal epithelial cells, myocardial cells, and neuronal 
cells, endothelial cells, pericytes, and vascular smooth 
muscle cells [18]. The common manifestation of FD in 
male patients with the classic form is acroparesthesias, 
hypohidrosis, corneal opacities, and kidney, brain, and 
heart dysfunction [23]. As the complaint of our case in 
this study, angina and dyspnea are common in cardiac 
involvement, and these symptoms reported in almost 
40-60% of patients with FD [24, 25]. As seen in the case 
of this study, Left ventricular structural abnormalities 
are a vital feature of cardiac involvement in 
echocardiographic studies. As observed in our study, in 
most cases, LVH is concentric [26]. Also, 
electrocardiographic changes in patients with FD are 
generally related to LVH similar to us cases in this study. 
Other abnormalities of FD in ECG include ST-segment 
depression and T-wave inversions, a short PR interval 
due to a short P wave, widening QRS complex and 
prolonged QTC intervals, supraventricular tachycardia, 
atrioventricular node blocks, bundle branch blocks, and 
others arrhythmias [27]. 
Other cardiac manifestations in FD and symptom/sign 
of other organs involvement shown in Table 1. 
 
Table 1. Symptoms and Signs of Fabry disease 
Organ Symptoms/Signs 
Heart Impaired heart rate variability, ECG abnormalities (shortened PR interval), Arrhythmias, Mild valvular insufficiency, 
Aortic root dilatation 
Nervous system Acroparesthesias, headache, vertigo/dizziness, transient ischemic attacks, ischemic strokes, Heat intolerance, tinnitus, 
vascular dementia 
Skin Angiokeratomas, Absence or ability of sweating, heat and exercise intolerance 
Gastrointestinal tract Nausea, vomiting, diarrhea, abdominal pain after eating, early satiety, Difficulty gaining weight 
Kidneys Microalbuminuria, proteinuria, Increased GFR, Renal failure 
Eyes Corneal and lenticular opacities, tortuosity of the conjunctival and retinal vessels 
Auditory and 
vestibular 
hearing loss, tinnitus and vertigo 
Respiratory Exertional dyspnea, chronic cough and wheezing, airway obstruction, 
Skeletal Osteopenia or osteoporosis 
Miscellaneous Chronic fatigue, weight loss, Impaired concentration ability, anemia, depression, azoospermia, hypothyroidism, 
lymphedema, priapism 
 
Differential Diagnosis and Diagnosis 
Differentiate of FD from other causes of LVH, such as 
other myocardial storage diseases such as amyloidosis, 
hypertrophic cardiomyopathy, or hypertensive heart 
disease, is difficult. Using symptom, echocardiographic 
findings, and ECG may help to differentiate FD from 
another differential diagnosis in unexplained LVH [28]. 
Other differential diagnoses of FD include rheumatic 
fever, systemic lupus erythematosus, Reynold's disease, 
celiac disease, and sclerosis, and growing disease (in 
children with FD) should be ruled out in unexplained 
LVH [29]. 
In male patients with FD Evaluation of the α-gal, A 
enzymatic activity in plasma is a useful method for the 
diagnosis of FD [30]. Autopsy shows cardiac storage of 
ceramide trihexoside in classical cases of FD [31]. 
Prenatal diagnosis determines by α-gal A activity in 
chorionic villi at ten weeks of pregnancy or in cultured 
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amniotic cells at about 14 weeks of pregnancy [32]. The 
differential diagnosis of FD from hypertrophic 
cardiomyopathy is essential because effective enzyme 
enhancement therapy and ERT for FD has recently been 
made available [33]. 
Treatment 
Treatment and management of FD are supportive, 
including comprehensive treatment by ERT [34], 
conventional medical treatment [35], and adjunctive 
therapies [36]. In cardiac involvement, the differential 
diagnosis of FD from hypertrophic cardiomyopathy is 
critical clinically and outcome because β-blockers, Ca-
blockers, and disopyramide generally used in 
hypertrophic cardiomyopathy, may be contraindicated 
in Fabry cardiomyopathy patients [12]. In addition; 
although, there are few data on the effectiveness of 
enzyme therapy on cardiac involvement in FD [7], 
enzyme replacement therapy help to resolve of 
glycolipid accumulation in myocytes, and returns some 
aspects of the cardiac relationship such as LVH and mass 
and help improvement in cardiac function [12]. 
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